Brought to you by 
Immunocore brings in record $320mm through Series A round
15 Sep 2017
Executive Summary
Immunocore Ltd. (T-cell receptor-based therapies for cancer, infections, and autoimmune diseases) raised $320mm through its Series A round. New investors Woodford Investment Management, partner Eli Lilly & Co., RTW Investments, and Malin Corp. PLC (which invested $80mm) participated, along with additional new and returning buyers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immunocore brings in record $320mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice